Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCL2 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BCL2 rearrangement	Diffuse Large B Cell Lymphoma	BCL2 rearrangement	Diffuse Large B Cell Lymphoma	rituximab Sensitive: C2 – Inclusion Criteria rituximab Sensitive : C2	rituximab Sensitive: C2 – Inclusion Criteria rituximab Sensitive : C2
BCL2 rearrangement	Lymphoma	BCL2 rearrangement	Lymphoma	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3	CAR-T immunotherapy Resistant: C3 – Early Trials CAR-T immunotherapy Resistant : C3
BCL2 rearrangement	Diffuse Large B Cell Lymphoma	BCL2 rearrangement	Diffuse Large B Cell Lymphoma	EPOCH-R Sensitive: C3 – Early Trials EPOCH-R Sensitive : C3	EPOCH-R Sensitive: C3 – Early Trials EPOCH-R Sensitive : C3